Group 1 - The core viewpoint of the article highlights the performance and financial results of BGM, which saw a stock price increase of 6.71% to $9.625 per share, with a total market capitalization of $1.771 billion as of July 31 [1] - As of March 31, 2025, BGM reported total revenue of $14.3114 million, reflecting a year-on-year growth of 13.92%, while the net profit attributable to shareholders was a loss of $0.8612 million, a significant decrease of 307.79% compared to the previous year [1] - BGM, formerly known as Qilian International Holdings Group, is based in Chengdu, China, and focuses on innovative sectors such as biopharmaceuticals, bio-extraction, and healthcare [1] Group 2 - The company's product range includes tetracycline raw materials, licorice preparations, and crude heparin sodium, which are essential for both human antibiotics and the global livestock industry [1] - Tetracycline raw materials support the production of human antibiotics and ensure the safety of poultry and seafood in the livestock sector [1] - Crude heparin sodium is processed by downstream companies into refined heparin sodium and injectable heparin sodium solutions, serving as a primary anticoagulant [1]
博美集团上涨6.71%，报9.625美元/股，总市值17.71亿美元